The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Will Be The Estimated Market Size Of The Recombinant Vaccines Market By 2030?

The recombinant vaccines market has expanded significantly over recent years. This market is anticipated to increase from $15.79 billion in 2025 to $17.69 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.0%. Factors such as the successful deployment of hepatitis B recombinant vaccines, established global vaccination schemes, heightened awareness of viral illnesses, increased funding for immunization, and supportive regulations for safer vaccine platforms have contributed to its historical growth.

The recombinant vaccines market size is anticipated to experience substantial growth in the upcoming years. It is projected to expand to $28.07 billion in 2030, achieving a compound annual growth rate (CAGR) of 12.2%. This anticipated growth during the forecast period can be attributed to factors such as an increasing demand for precision vaccines, the expansion of vaccines for emerging diseases, a rise in adult booster programs, increasing global immunization coverage, and a robust pipeline of recombinant candidates. Furthermore, major trends expected in this period include an increase in recombinant subunit vaccines, the expansion of vector-based vaccine platforms, more comprehensive adult immunization programs, the development of combination recombinant vaccines, and a heightened focus on ensuring long-duration immunity.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33287&type=smp

What Core Drivers Are Transforming The Recombinant Vaccines Market?

The growing incidence of infectious diseases is anticipated to boost the expansion of the recombinant vaccines market in the future. An infectious disease originates from microorganisms like bacteria, viruses, fungi, or parasites and has the capability to transmit between individuals, either directly or indirectly. The rise in infectious disease prevalence stems from inadequate sanitation and hygiene, as insufficient access to clean water, proper sanitation, and efficient waste disposal facilitates the rapid spread of detrimental microorganisms via tainted food, water, and personal contact, consequently elevating infection risks. Recombinant vaccines aid in preventing infectious diseases through the utilization of genetically engineered material derived from pathogens, which provokes an immune response without inducing sickness. For example, in July 2024, data from the Australian Institute of Health and Welfare, an Australia-based national agency, indicated that over 109,000 chlamydia and more than 40,000 gonorrhea notifications were the most frequently reported sexually transmitted infections in Australia in 2023, alongside more than 6,400 infectious syphilis cases, underscoring the rising occurrence and persistent public health challenges. Consequently, the expanding occurrence of infectious diseases is propelling the growth of the recombinant vaccines market.

What Are The Major Segment Categories Within The Recombinant Vaccines Market?

The recombinant vaccines market covered in this report is segmented –

1) By Type: Subunit Vaccines; Vector-Based Vaccines

2) By Disease Indication: Human Papillomavirus (HPV); Herpes Zoster; Hepatitis B; Other Diseases

3) By Route Of Administration: Parenteral; Other Route Of Administrations

4) By End User: Pediatric; Adults

Subsegments:

1) By Subunit Vaccines: Protein Subunit Vaccines; Polysaccharide Subunit Vaccines; Conjugate Subunit Vaccines; Glycopeptide Subunit Vaccines; Recombinant Subunit Vaccines

2) By Vector-Based Vaccines: Viral Vector Vaccines; Non Viral Vector Vaccines; Replicating Vector Vaccines; Non Replicating Vector Vaccines; Bacterial Vector Vaccines

What Trends Are Impacting The Recombinant Vaccines Market?

Companies operating in the recombinant vaccines market are prioritizing the creation of innovative vaccines, such as the recombinant 9-valent HPV vaccine, to secure a competitive advantage. This recombinant 9-valent HPV vaccine provides protection against nine types of human papillomavirus (HPV) and is produced using recombinant DNA technology, indicating its laboratory creation without live viruses, which aids in preventing HPV-related illnesses like cervical cancer and genital warts. For instance, in August 2023, Jiangsu Recbio Technology Co. Ltd., a China-based biopharmaceutical company, moved its recombinant 9-valent HPV vaccine, REC603, through Phase III clinical follow-up, involving ongoing 24-month observations. The vaccine showcased strong immunogenicity, a favorable safety profile, scalable manufacturing potential, and long-term efficacy, thereby supporting its potential for extensive HPV prevention and commercialization.

Which Organizations Are Operating Within The Recombinant Vaccines Market?

Major companies operating in the recombinant vaccines market are Johnson And Johnson, Merck And Co Inc., Pfizer Inc., Sanofi S. A., Novartis AG, AstraZeneca Plc, GlaxoSmithKline Plc, Mitsubishi Chemical Group Corporation, CSL Limited, Sinovac Biotech Ltd., Boehringer Ingelheim International GmbH, Zoetis Services Llc, Elanco Animal Health, BioNTech Se, Green Cross Corporation (Gc Biopharma), Bavarian Nordic A S, VBI Vaccines Inc., Vaxart Inc., Biological E Limited, Novavax Inc., Serum Institute Of India Private Limited, Vaxcyte Inc., Bharat Biotech International Limited, and Transgene S A.

Access The Complete Recombinant Vaccines Market Report:

https://www.thebusinessresearchcompany.com/report/recombinant-vaccines-market-report

Which Region Stands As The Largest Contributor To The Recombinant Vaccines Market?

North America was the largest region in the recombinant vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the recombinant vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Customized Recombinant Vaccines Market Report for Deeper Competitive Insights

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model